The abstract is read at the publisher; the summary is JClub's.
Risvutatug rezetecan improved BICR-assessed progression-free survival versus gemcitabine-docetaxel in Chinese patients with relapsed or refractory osteosarcoma, with median 5.5 vs 1.4 months (HR 0.33).
- Why it matters: Relapsed or refractory osteosarcoma has poor outcomes and limited effective options after multiple prior systemic treatments, creating a need for therapies that extend disease control.
- What they did: In ARTEMIS-011, a multicenter open-label randomized phase III trial in Chinese patients aged ≥12 years, Ris-Rez 12.0 mg/kg was compared with gemcitabine-docetaxel every 3 weeks, stratified by age and lung metastasis.
- The result: At data cut-off (17 June 2026), adverse events occurred in all patients; no treatment-related AEs led to death, while grade ≥3 TRAEs were 93% vs 83% and serious TRAEs 64% vs 29%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.